Linagliptina Billev

Linagliptin, the active ingredient in Linagliptina Billev, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptina Billev as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to lower blood glucose.

- Type 2 diabetes mellitus (monotherapy): improves fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (add‑on to metformin): provides additional glycaemic reduction when metformin alone is insufficient. - Type 2 diabetes mellitus with renal impairment: offers effective control without dose adjustment in patients with reduced kidney function.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Dizziness: occasional light‑headed sensation. - Gastrointestinal upset: nausea, abdominal discomfort. - Back pain: intermittent musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: angioedema, anaphylaxis, or rash. - Hepatic injury: marked elevation of liver enzymes. - Stevens‑Johnson syndrome: extensive skin blistering and detachment. - Hypoglycaemia (when combined with sulfonylureas or insulin): symptomatic low blood glucose. - Bullous pemphigoid: autoimmune blistering skin disease.

Linagliptin should be used with clinical monitoring and patient education. - Renal function: assess baseline renal status; dose adjustment not required but monitor progression. - Hepatic impairment: evaluate liver function before initiating therapy. - Hypoglycaemia risk: caution when combined with insulin or sulfonylureas; adjust concomitant agents as needed. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk; data are limited. - Allergic reactions: discontinue if signs of severe hypersensitivity appear. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Sulfonylureas or insulin: increased risk of hypoglycaemia; dose adjustments may be necessary. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin exposure and efficacy.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may modestly increase linagliptin plasma levels. - Diuretics: monitor electrolytes and renal function as volume changes can affect drug clearance. - Antihypertensives: observe blood pressure control as fluid shifts may occur.